Share Price:

APNASPENAspen Pharmacare Hldgs210740 (0.00%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Aspen increases revenue 16% to R41.2 bn

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading global pharmaceutical company, has announced pleasing results for the year ended 30 June 2017. Download (PDF 86.7KB)

Financial Mail cover story – 22 June 2017

Price gouging is not in Aspen’s DNA, says founder Stephen Saad, incensed at the thought that his company would exploit the sick. But Aspen’s predicament, and that of all drug firms, boils down to the tension between a drug company’s perceived responsibility to provide life-saving drugs to patients at a reasonable price, and its natural… Continue reading Financial Mail cover story – 22 June 2017

Partnering with the South African Department of Health to Enhance Public Healthcare

One of Aspen’s key business imperatives is the creation of stakeholder value. The communities Aspen operates within remain amongst the Group’s most important stakeholders, with healthcare being one of the key aspects to ensuring sustainable communities. While South Africa is currently burdened with one of the world’s most disproportionate disease profiles, it also has enthusiastic… Continue reading Partnering with the South African Department of Health to Enhance Public Healthcare

Aspen cleared of alleged anti-competitive behavior by DA

Durban – JSE Limited-listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has welcomed the statement issued by the Democratic Alliance (“DA”) earlier today in which it has confirmed that it is satisfied that there is no evidence that Aspen has engaged in alleged anti-competitive behavior as per the DA’s statement issued… Continue reading Aspen cleared of alleged anti-competitive behavior by DA

Aspen concludes strategic M.O.U with the Russian Federation

Windhoek, Namibia – JSE Limited listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has announced that a memorandum of understanding (“M.O.U”) has been concluded between Aspen’s Russian business and the Vladivostok Far Eastern Federal University (“F.E.F.U”). The Deputy Prime Minister of Russia Mr. Yury Trutnev, who has delegated authority from the… Continue reading Aspen concludes strategic M.O.U with the Russian Federation

Statement in response to The Times of London report on 20 May 2017 on Florinef

Having noted the report published in The Times of London on 20 May 2017 titled “Massive price rise for vital drug put pets’ lives at risk”, Aspen wishes to express its disappointment and concern that much of the information and clarification it provided to The Times’ Billy Kenber prior to the report being published has… Continue reading Statement in response to The Times of London report on 20 May 2017 on Florinef

Opening of European Commission proceedings

Aspen confirms that the European Commission has opened proceedings to investigate certain actions of Aspen Holdings and certain of its European subsidiaries. While Aspen is not currently in a position to comment on these proceedings, it reaffirms its commitment to fair and open competition in markets in the European Union and around the world. Aspen… Continue reading Opening of European Commission proceedings

Aspen’s response to the reported Competition Commission investigation

Durban – Media reports that the Competition Commission has decided to take up the Democratic Alliance’s request to investigate the alleged anti-competitive conduct of Aspen Pharmacare (“Aspen”) in South Africa, in its preliminary investigation into the pharmaceutical sector, has reference. Aspen welcomes the process and the opportunity to categorically set aside such allegations of anti-competitive… Continue reading Aspen’s response to the reported Competition Commission investigation

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.